<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="proliferate">
            <roleset id="proliferate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="thing becoming abundant&#x09;&#x09;&#x09;&#x09;// gene products //&#x0A;" />
                    <role n="1" descr="situation of becoming abundant&#x0A;" />
                    <role n="2" descr="location referring to organ, vitro&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely after the introduction of Stat5a wild body estuation (Figure 6B).</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A0 T cells are able to recover the ability to proliferate indefinitely when transferred to lymphocytic hosts (Figure 6B).</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A0, which is unique to adults, has the ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Adult T cells at rest, under normal conditions, may proliferate after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Adult T cells at rest, under normal conditions, may proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Adult T cells at rest, under normal conditions, may proliferated a sharp proliferation of when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Adult T cells, at rest under normal conditions, have the ability to proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Adult T cells, at rest, under normal conditions, proliferate strongly transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Adult T cells, which are at rest in normal conditions, are proliferate as proliferative cells when transferred to lymphonic hosts.</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Adult T cells, which are at rest in normal conditions, have the ability to proliferate strongly when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Adult T cells, which are at rest under normal conditions, are proliferate for the proliferation of when transferred to lymph nodes.</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Adult T cells, which are at rest under normal conditions, can proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Adult T cells, which are at rest under normal conditions, have strongly proliferated after the introduction of Stat5a wild body estuation.</text>
                    <arg n="1">after the introduction of Stat5a wild body estuation</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Adult T cells, which are at rest under normal conditions, may have proliferated transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Adult T cells, which are at rest under normal conditions, may have strongly proliferated transferred to lymph nodes.</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Adult T cells, which are at rest under normal conditions, proliferate strongly transferred to lymphonic hosts.</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>After androgen withdrawal and angiogen treatment, Stat5ab-/-peripheral T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>After androgen withdrawal and angiogen treatment, androgen-responsive prostate cancer cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells from the androgen prostate will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells of the androgen prostate will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>After androgen withdrawal and angiogen treatment, cancer cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>After androgen withdrawal and angiogen treatment, endothelial cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>After androgen withdrawal and angiogen treatment, prostate cancer cells respond to androgen may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/-peripheral T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>After androgen withdrawal and angiogen treatment, stat5ab/peripheral T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>After androgen withdrawal and anti-androgen treatment, Stat5ab-/-peripheral T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>After androgen withdrawal and anti-androgen treatment, allergen prostate cancer cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen prostate cancer cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen tumour cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>After androgen withdrawal and anti-androgen treatment, androgenic responsive prostate cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>After androgen withdrawal and anti-androgen treatment, cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>After androgen withdrawal and anti-androgen treatment, carcinogenic cells of the prostate that respond to the androgen which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>After androgen withdrawal and anti-androgen treatment, endothelial cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells respond to androgen failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>After androgen withdrawal and anti-androgen treatment, prostate cancer cells responding to androgen which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab-/-peripheral T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/-peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>After androgen withdrawal and anti-androgen treatment, stat5ab/peripheral T cells will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>After androgen withdrawal and antiandrogen treatment, Stat5ab-/-peripheral T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>After androgen withdrawal and antiandrogen treatment, allergen prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>After androgen withdrawal and antiandrogen treatment, carcinogenic cells of the prostate that respond to the androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>After androgen withdrawal and antiandrogen treatment, prostate cancer cells respond to androgen ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>After androgens have been removed and anti-androgen treatment, Stat5ab-/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>After androgens have been removed and anti-androgen treatment, androgen-responsive prostate cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>After androgens have been removed and anti-androgen treatment, cancer cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>After androgens have been removed and anti-androgen treatment, stat5ab/-peripheral T cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>After the androgen has been withdrawn and angiogen treatment, Stat5ab-/-peripheral T cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>After the androgen has been withdrawn and angiogen treatment, Stat5ab-/-peripheral T cells will proliferate tumor regression.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>After the androgen has been withdrawn and angiogen treatment, allergen prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen prostate cancer cells will proliferate tumor regression.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen tumour cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen-responsive prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgenic responsive prostate cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgenic responsive prostate cancer cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>After the androgen has been withdrawn and angiogen treatment, cancer cells will proliferate tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>After the androgen has been withdrawn and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>After the androgen has been withdrawn and angiogen treatment, carcinogenic cells of the prostate that respond to the androgen which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells respond to androgen will proliferate tumor regression.</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>After the androgen has been withdrawn and angiogen treatment, prostate cancer cells responding to androgen which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>After the androgen has been withdrawn and angiogen treatment, stat5ab/peripheral T cells will proliferate tumor regression.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, allergen prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgenic responsive prostate cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, stat5ab-/-peripheral T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>HD CD4+ T cells specific for HIV in viremic patients is likely to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>HD CD4+ T cells specific for HIV in viremic patients may continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>HIV-specific CD4+ T cells in viremic patients is likely to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>HIV-specific CD4+ T cells in viremic patients may continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>HIV-specific CD4+ T cells in viremic patients may continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>HIV-specific CD4+ T cells in viremic patients will continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HIV-specific CD4+ T cells in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>HIV-specific T cells CCD4+ in viremic patients is able to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>HIV-specific T cells CCD4+ in viremic patients is observed to continue to proliferate in vitro when co-stimulation was provided by anti-CD28 antibodies, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HIV-specific T cells CCD4+ in viremic patients</arg>
                    <arg n="1">when co-stimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>HSC continued to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>HSC continued to proliferate strongly in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>HSC has the ability to continue to proliferate in bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>HSC is a disease that proliferate with great proliferation in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>HSC is a disease that proliferate with great proliferation in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tends to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>HSC is likely to continue to proliferate in the bone marrow and spleen via 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of G-CSF treatment</arg>
                    <arg n="2">in the bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>HSC is likely to continue to proliferate strongly in bone marrow and splendor roughly 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>HSC is observed to continue to proliferate in bone marrow and spleen via 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">via 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>HSC may continue to proliferate in bone marrow and spleen with 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">with 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>HSC may continue to proliferate strongly in bone marrow and spleen through 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>HSC may continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/ G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>HSC may have continued to proliferate strongly in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>HSC will continue to proliferate strongly in bone marrow and splendor approximately 8 days of treatment with G-CSF, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">approximately 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>In addition, BI cells may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>In addition, BT cells has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>In addition, BT cells may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>In addition, BT cells proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients has been found to proliferate strongly in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>In addition, CCD4+ HIV-specific cells of viremic patients was observed to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>In addition, EBD cells has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>In addition, HD CD4+ T cells specific for HIV in viremic patients has been shown to be highly proliferating in response to HIV antigens when costimulation was provided by anti-CD28 antibodies in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="1">when costimulation was provided by anti-CD28 antibodies</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients has been found to proliferate strongly in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>In addition, HD CD4+ T cells specific to HIV in viremics patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>In addition, HD-specific T CD4+ cells for HIV in viremic patients proliferated in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>In addition, HIV-specific A0, CD4+T cells from viremic patients were found to proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibody) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>In addition, HIV-specific T-cells CCD4+ in viraemic patients may be observed to proliferate in response to HIV A1 antigens (when co-stimulation was provided by anti-CD28 antibodies) in vitro.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>In addition, HSC is able to proliferate in response to HIV antigens roughly 8 days of treatment with G-CSF in bone marrow and splendor.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">roughly 8 days of treatment with G-CSF</arg>
                    <arg n="2">in bone marrow and splendor</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>In addition, it has been shown that HIV-specific CD4+T blood cells in viremic patients proliferate in response to HIV A1 antigens (when the costimulation was provided by anti-CD28 antibodies) in vivo.</text>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>It is observed that HSC continues to proliferate in bone marrow and spleen through 8 days of G-CSF treatment, but HSC released in the blood tended to be in the G0/G1 phase.</text>
                    <arg n="0">HSC</arg>
                    <arg n="1">through 8 days of G-CSF treatment</arg>
                    <arg n="2">in bone marrow and spleen</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>It is observed that Stat5ab-/-peripheral T cells regains the ability to proliferate indefinitely after the introduction of the Stat5a type of complete wild size (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>It is observed that Stat5ab/-peripheral T cells regains the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>It is observed that ingenue T cells of adults regains the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>It is observed that stat5ab/peripheral T cells regains the ability to proliferate after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>It is observed that the human placenta regains the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>It is proliferate that adult naive T cells regains the undefined proliferation capability when transferred to lymphopenic hosts (image 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>It is proliferate that ingenue T cells of adults regains the undefined proliferation capability when transferred to lymphonic hosts (image 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>It is proliferate that stat5ab/peripheral T cells regains the undefined proliferation capability after the introduction of the full wild-length state5a (image 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>It is proliferate that the human placenta regains the undefined proliferation capability along gestation (image 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full-length wild type Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a stulation, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>Our observations illustrate that Stat5ab-/-peripheral T cells was endowed with biochemical machinery to proliferate indefinitely after the introduction of Stat5a of full-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>Our observations illustrate that Stat5ab/-peripheral T cells can be endowed with biochemical machinery to proliferate after the introduction of the Stat5a complete-length wild type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>Our observations illustrate that adult T cells has been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>Our observations illustrate that adult naive T cells can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>Our observations illustrate that adult naive T cells can be endowed with biochemical machinery to proliferate when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>Our observations illustrate that adult naive T cells could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>Our observations illustrate that adult naive T cells is endowed with biochemical machinery to proliferate indefinitely when transferred to lymphopenic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>Our observations illustrate that endothelial cells has been endowed with biochemical machinery to proliferate indefinitely when exposed to FGF2, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>Our observations illustrate that ingenue T cells of adults can be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>Our observations illustrate that ingenue T cells of adults can be endowed with biochemical machinery to proliferate when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>Our observations illustrate that ingenue T cells of adults could have been endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells could have been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a type, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>Our observations illustrate that stat5ab-/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length Stat5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells can be endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>Our observations illustrate that stat5ab/-peripheral T cells is endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>Our observations illustrate that stat5ab/peripheral T cells has been endowed with biochemical machinery to proliferate indefinitely after the introduction of the full wild-length state5a, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>Stat5ab-/-peripheral T cells has regained the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>Stat5ab-/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>Stat5ab-/-peripheral T cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>Stat5ab-/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the Stat5a type of complete wild size (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>Stat5ab-/-peripheral T cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>Stat5ab-/-peripheral T cells proliferate the undefined proliferation capacity after the introduction of Stat5a of full-length wild type (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>Stat5ab-/-peripheral T cells recovered the ability to proliferate after the introduction of the Stat5a type of complete wild size (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>Stat5ab-/-peripheral T cells regained the ability to proliferate indefinitely after the introduction of wild body stat5a (Figure 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>Stat5ab-/-peripheral T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, have the ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>Stat5ab-/-peripheral T cells, which are at rest under normal conditions, are observed to strongly proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>Stat5ab/-peripheral T cells can regain the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Stat5ab/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Stat5ab/-peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the Stat5a complete-length wild type (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Stat5ab/-peripheral has the probability of recovering the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Stat5ab/-peripheral may have regained the ability to proliferate after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Stat5ab/-peripheral will regain the ability to proliferate indefinitely after the introduction of Stat5a stulation (Figure 6B).</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity transferred to lymph nodes (picture 6B).</text>
                    <arg n="1">transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="1">transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity when transferred to lymph nodes (picture 6B).</text>
                    <arg n="1">when transferred to lymph nodes</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>T A0 cells are able to proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>T cells ingenue T cells of adults are able to recover the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>The BI cells capacity that will proliferate strongly in vivo has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>The CCD4+ HIV-specific T cells of viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>The CCD4+ HIV-specific cells of viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>The EBD cells capacity that proliferated in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>The HD CD4+ T cells specific for HIV in viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>The HD CD4+ T cells specific for HIV in viremic patients capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>The HD-specific T CD4+ cells for HIV in viremic patients capacity that proliferated in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>The ability of A0 cells (BT) to proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>The ability of BI cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>The ability of BT cells that have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>The ability of BT cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>The ability of BT cells to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BT cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>The ability of CCD4+ HIV-specific T cells of viremic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific T cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that have proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>The ability of CCD4+ HIV-specific cells of viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>The ability of EBD cells that was observed to proliferate strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">EBD cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>The ability of HD CD4+ T cells specific for HIV in viremic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that have the ability to proliferate strongly in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>The ability of HD CD4+ T cells specific to HIV in viremics patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>The ability of HD-specific T CD4+ cells for HIV in viremic patients that can proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that is capable of proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that is capable of strongly proliferating in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>The ability of HDCD4+ T cells specific to HIV in viremics patients that may have strongly proliferated in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HDCD4+ T cells specific to HIV in viremics patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that is able to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>The ability of HIV-specific T-cells CCD4+ in viraemic patients to proliferate in vitro was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HIV-specific T-cells CCD4+ in viraemic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>The ability to proliferate in vitro was examined by injection of 3? 106 LVTE cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>The ability to proliferate strongly in vitro was examined by injection of 3? 106 CVC cells into the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>The capacity of BI cells that may have proliferated strongly in vivo was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">BI cells</arg>
                    <arg n="2">in vivo</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>The capacity of CCD4+ HIV-specific cells of viremic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CCD4+ HIV-specific cells of viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>The capacity of HD-specific T CD4+ cells for HIV in viremic patients that may have proliferated strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">HD-specific T CD4+ cells for HIV in viremic patients</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of Stat5a of full-length wild type.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a of full-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>The treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>The treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoilamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrolidino-1-propanol-HCl, significantly impaired its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>The treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is able to significantly impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>The treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>The treatment of adult naive T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>The treatment of allergen prostate cancer cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>The treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of wild body stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of wild body stat5a</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the Stat5a type of complete wild size.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a type of complete wild size</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full-length wild type Stat5a.</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full-length wild type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">Stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Treatment of Stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the Stat5a complete-length wild type.</text>
                    <arg n="0">Stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the Stat5a complete-length wild type</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Treatment of Stat5ab/-peripheral of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of Stat5a stulation.</text>
                    <arg n="0">Stat5ab/-peripheral</arg>
                    <arg n="1">after the introduction of Stat5a stulation</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Treatment of adult T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>Treatment of allergen prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>Treatment of androgen prostate cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>Treatment of androgen prostate cancer cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>Treatment of androgen-responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Treatment of androgenic responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Treatment of cancer cells from the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Treatment of cancer cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Treatment of cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Treatment of cancer cells of the androgen prostate of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Treatment of carcinogenic cells of the prostate that respond to the androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">carcinogenic cells of the prostate that respond to the androgen</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Treatment of prostate cancer cells respond to androgen of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">prostate cancer cells respond to androgen</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Treatment of prostate cancer cells responding to androgen of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length Stat5a type.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a type</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Treatment of stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate after the introduction of the full wild-length state5a.</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Treatment of stat5ab/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate after the introduction of the completely length wild-type Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Treatment of stat5ab/peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>adult T cells has regained the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>adult T cells has the probability of recovering the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>adult T cells proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>adult T cells recovered the ability to proliferate when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>adult naive T cells has the probability of recovering the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>adult naive T cells may have regained the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>adult naive T cells, which are at rest in normal conditions, are observed to proliferate when transferred to lymphopenic hosts.</text>
                    <arg n="0">adult naive T cells</arg>
                    <arg n="1">when transferred to lymphopenic hosts</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>allergen prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>allergen prostate cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>allergen prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">allergen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>androgen prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>androgen prostate cancer cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">androgen prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>androgen tumour cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>androgen tumour cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">androgen tumour cells</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>androgen-responsive prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgen-responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>androgenic responsive prostate cancer cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>androgenic responsive prostate cancer cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgenic responsive prostate cancer cells</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>cancer cells from the androgen prostate is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>cancer cells from the androgen prostate proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">cancer cells from the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>cancer cells of the androgen prostate will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">cancer cells of the androgen prostate</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>endothelial cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>endothelial cells may have regained the ability to proliferate when exposed to FGF2 (Figure 6B).</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>endothelial cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">endothelial cells</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>endothelial cells, which are at rest under normal conditions, are able to proliferate strongly when exposed to FGF2.</text>
                    <arg n="0">endothelial cells</arg>
                    <arg n="1">when exposed to FGF2</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>ingenue T cells of adults can regain the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>ingenue T cells of adults has the probability of recovering the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>ingenue T cells of adults may have regained the ability to proliferate indefinitely when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>ingenue T cells of adults may proliferate the undefined proliferation capacity when transferred to lymphonic hosts (picture 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>ingenue T cells of adults will regain the ability to proliferate when transferred to lymphonic hosts (Figure 6B).</text>
                    <arg n="0">ingenue T cells of adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>prostate cancer cells responding to androgen proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">prostate cancer cells responding to androgen</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>stat5ab-/-peripheral T cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely after the introduction of the full wild-length Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>stat5ab-/-peripheral T cells, which are at rest under normal conditions, can proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab-/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>stat5ab/-peripheral T cells has the probability of recovering the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>stat5ab/-peripheral T cells may proliferate the undefined proliferation capacity after the introduction of the full wild-length state5a (picture 6B).</text>
                    <arg n="0">stat5ab/-peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>stat5ab/peripheral T cells can regain the ability to proliferate indefinitely after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>stat5ab/peripheral T cells has regained the ability to proliferate after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate after the introduction of the completely length wild-type Stat5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>stat5ab/peripheral T cells may have regained the ability to proliferate indefinitely after the introduction of the full wild-length state5a (Figure 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length state5a</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>stat5ab/peripheral T cells may proliferate recovered the undefined proliferation capacity after the introduction of the completely length wild-type Stat5a (picture 6B).</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the completely length wild-type Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>stat5ab/peripheral T cells, which are at rest in normal conditions, are observed to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>stat5ab/peripheral T cells, which are at rest under normal conditions, are able to proliferate after the introduction of the full wild-length Stat5a.</text>
                    <arg n="0">stat5ab/peripheral T cells</arg>
                    <arg n="1">after the introduction of the full wild-length Stat5a</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>the human placenta may have regained the ability to proliferate along gestation (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>the human placenta may proliferate the undefined proliferation capacity along gestation (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>the human placenta, which are at rest under normal conditions, can proliferate along gestation.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">along gestation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>After androgen withdrawal and angiogen treatment, CD4+ HIV T cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>After androgen withdrawal and angiogen treatment, EBD cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>After androgen withdrawal and angiogen treatment, TBI cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>After androgen withdrawal and angiogen treatment, adult T cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>After androgen withdrawal and angiogen treatment, androgen cancer cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplenically which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>After androgen withdrawal and angiogen treatment, feet cells transplanted intrasplentically may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>After androgen withdrawal and angiogen treatment, fetal liver cells transplanted intrasplenically which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>After androgen withdrawal and angiogen treatment, human placenta may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>After androgen withdrawal and angiogen treatment, human placenta which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>After androgen withdrawal and angiogen treatment, ingenue T cells for adults which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>After androgen withdrawal and angiogen treatment, intra-splate transplant feet cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells which ceased proliferation and were submitted to proliferate caused tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>After androgen withdrawal and angiogen treatment, intra-splenic transplant fetal cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>After androgen withdrawal and angiogen treatment, intra-splintly transplanted fetal shapes was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>After androgen withdrawal and angiogen treatment, intrasplens transplanted liver cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>After androgen withdrawal and angiogen treatment, intrasplensally transplanted liver cells which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>After androgen withdrawal and angiogen treatment, intrasplintly transplanted fetal cells will cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells able to interrupt proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>After androgen withdrawal and angiogen treatment, intrasponntically transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>After androgen withdrawal and angiogen treatment, intraspontically transplanted fetal cells was proliferate to trigger apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>After androgen withdrawal and angiogen treatment, the human placenta which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>After androgen withdrawal and angiogen treatment, transplant feet cells intrasplenomegaly which stopped proliferating and submitted to apoptosis caused tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>After androgen withdrawal and anti-androgen treatment, CD4+ HIV T cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>After androgen withdrawal and anti-androgen treatment, EBD cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>After androgen withdrawal and anti-androgen treatment, HD CD4+ T cells specific to HIV in viremics patients failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>After androgen withdrawal and anti-androgen treatment, TBI cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>After androgen withdrawal and anti-androgen treatment, adult T cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>After androgen withdrawal and anti-androgen treatment, androgen cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>After androgen withdrawal and anti-androgen treatment, androgens responsive prostate cancer cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>After androgen withdrawal and anti-androgen treatment, angiogen prostate cancer cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplenically will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>After androgen withdrawal and anti-androgen treatment, feet cells transplanted intrasplentically ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>After androgen withdrawal and anti-androgen treatment, fetal liver cells transplanted intrasplenically has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>After androgen withdrawal and anti-androgen treatment, human placenta will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells for adults failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults ceases to proliferate and suffers apoptosis, causing tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>After androgen withdrawal and anti-androgen treatment, ingenue T cells of adults is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splate transplant feet cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>After androgen withdrawal and anti-androgen treatment, intra-splintly transplanted fetal shapes which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplens transplanted liver cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplensally transplanted liver cells is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasplintly transplanted fetal cells which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>After androgen withdrawal and anti-androgen treatment, intrasponntically transplanted fetal cells which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells failed to proliferate and suffer apoptosis cause tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>After androgen withdrawal and anti-androgen treatment, intraspontically transplanted fetal cells may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>After androgen withdrawal and anti-androgen treatment, the human placenta which have the ability to cease to proliferate and to suffer apoptosis cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly has the ability to cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly is able to stop proliferation and suffer apoptosis, proliferate tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly may cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly which will cease to proliferate and undergo apoptosis will cause tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>After androgen withdrawal and anti-androgen treatment, transplant feet cells intrasplenomegaly will cease to proliferate and suffer apoptosis, causing tumor regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>After androgen withdrawal and antiandrogen treatment, EBD cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>After androgen withdrawal and antiandrogen treatment, adult T cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>After androgen withdrawal and antiandrogen treatment, androgen cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>After androgen withdrawal and antiandrogen treatment, androgens responsive prostate cancer cells ceased to proliferate and underwent apoptosis, causing tumor regression.</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>After androgen withdrawal and antiandrogen treatment, angiogen prostate cancer cells ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">angiogen prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>After androgen withdrawal and antiandrogen treatment, the human placenta ceased to proliferate and suffered apoptosis causing tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>After androgens have been removed and anti-androgen treatment, EBD cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>After androgens have been removed and anti-androgen treatment, EBD cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>After androgens have been removed and anti-androgen treatment, human placenta which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>After androgens have been removed and anti-androgen treatment, ingenue T cells for adults which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>After androgens have been removed and anti-androgen treatment, ingenue T cells of adults that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">ingenue T cells of adults</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>After androgens have been removed and anti-androgen treatment, intra-splenic transplant fetal cells which may cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplens transplanted liver cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>After androgens have been removed and anti-androgen treatment, intrasplensally transplanted liver cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>After androgens have been removed and anti-androgen treatment, intrasponntically transplanted fetal cells that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>After androgens have been removed and anti-androgen treatment, the human placenta that are observed to cease to proliferate and suffer apoptosis will cause tumor regression.</text>
                    <arg n="0">the human placenta</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>After the androgen has been withdrawn and angiogen treatment, EBD cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>After the androgen has been withdrawn and angiogen treatment, HD CD4+ T cells specific to HIV in viremics patients will proliferate tumor regression.</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>After the androgen has been withdrawn and angiogen treatment, androgen cancer cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>After the androgen has been withdrawn and angiogen treatment, feet cells transplanted intra-splintly which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>After the androgen has been withdrawn and angiogen treatment, fetal liver cells transplanted intrasplenically will proliferate tumor regression.</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>After the androgen has been withdrawn and angiogen treatment, ingenue T cells for adults which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splate transplant feet cells will proliferate tumor regression.</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splenic transplant fetal cells will proliferate tumor regression.</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>After the androgen has been withdrawn and angiogen treatment, intra-splintly transplanted fetal shapes will proliferate tumor regression.</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplens transplanted liver cells will proliferate tumor regression.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplensally transplanted fetal cells which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasplintly transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>After the androgen has been withdrawn and angiogen treatment, intrasponntically transplanted fetal cells which may cease to proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>After the androgen has been withdrawn and angiogen treatment, intraspontically transplanted fetal cells that are able to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>After the androgen has been withdrawn and angiogen treatment, intraspontically transplanted fetal cells which have the ability to prevent proliferation and suffer apoptosis will proliferate tumour regression.</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>After the androgen has been withdrawn and angiogen treatment, transplant feet cells intrasplenomegaly which will no longer proliferate and suffer apoptosis will cause tumour regression.</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, adult T cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>After the withdrawal of androgen and the treatment of anthandrogen, androgen cancer cells stopped proliferating and subjected to apoptosis, causing tumor regression.</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>CD4+ HIV T cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>CD4+ HIV T cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>CD4+ HIV T cells will proliferate the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>EBD cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>EBD cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>EBD cells may proliferate recovered the A1 proliferation capacity (after the introduction of the full-slaughtered Stat5a) (picture 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>EBD cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>It is observed that human placenta regains the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>It is observed that the human placenta regains the ability to proliferate indefinitely during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Our observations illustrate that human placenta will be endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Our observations illustrate that ingenue T cells for adults will be endowed with biochemical machinery to proliferate indefinitely when transferred to lymphonic hosts, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Our observations illustrate that the human placenta has been endowed with biochemical machinery to proliferate indefinitely during pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Our observations illustrate that the human placenta has been endowed with biochemical machinery to proliferate indefinitely through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Our observations illustrate that the human placenta was endowed with biochemical machinery to proliferate through pregnancy, however, there are intrinsic mechanisms that effectively circumscribe the extent and duration of proliferation of troblasts.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>T cells the human placenta are able to recover the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>TBI cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>The CD4+ HIV T cells capacity that will proliferate strongly in vitro has been examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>The ability of CD4+ HIV T cells that was observed to proliferate strongly in vitro was examined by injection of 3? 106 LVTE cells in the calf muscle of 3 immunocompromised mice.</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                    <arg n="2">in vitro</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>The treatment of EBD cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>The treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>The treatment of human placenta of different origin with inhibitors of the gastrosine gastoside fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has significantly impaired its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>The treatment of ingenue T cells for adults of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>The treatment of intrasplensally transplanted liver cells of different origin with inhibitors of the gastosine biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylamine-3-pyrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>The treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>The treatment of the human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>Treatment of CD4+ HIV T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">CD4+ HIV T cells</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>Treatment of EBD cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>Treatment of EBD cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has impaired its ability to proliferate A1 (when exposed to</text>
                    <arg n="0">EBD cells</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>Treatment of HD CD4+ T cells specific to HIV in viremics patients of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">HD CD4+ T cells specific to HIV in viremics patients</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>Treatment of TBI cells of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>Treatment of TBI cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">TBI cells</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>Treatment of adult T cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>Treatment of adult T cells of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is capable of impairing its ability to proliferate when transferred to lymphocytic hosts.</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to significantly proliferate its proliferation</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>Treatment of adult T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">adult T cells</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>Treatment of androgen cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>Treatment of androgens responsive prostate cancer cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">androgens responsive prostate cancer cells</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>Treatment of feet cells transplanted intra-splintly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">feet cells transplanted intra-splintly</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>Treatment of feet cells transplanted intrasplenically of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoila-1-pyrolidine-1-propanol-HCl is able to impair its A1 proliferation capability (when proliferate</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with inhibitors of the biosynthesis of fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl will impair its ability to proliferate A1 (exposed to FGF2</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>Treatment of feet cells transplanted intrasplentically of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>Treatment of human placenta of different origin with inhibitors of the biosynthesis of fumonisine gangliosides B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, will impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>Treatment of human placenta of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, is observed to significantly impair its ability to proliferate pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>Treatment of human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the ganglioside biosynthesis fumonisine B1, D-threo-1-phenyl-2-decanoilo-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, has the ability to significantly impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>Treatment of ingenue T cells for adults of different origin with inhibitors of the gastrosine gastrosine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-decanoylmino-3-pyrolidino-1-propanol-HCl, has the ability to impair its ability to proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>Treatment of ingenue T cells for adults of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>Treatment of intra-splate transplant feet cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>Treatment of intra-splate transplant feet cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>Treatment of intra-splenic transplant fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with lymphosid biosynthesis inhibitors fumonisin B1, D-treat-1-phenyl-2-decanoyl-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrrolidine-1-propanol-HCl is observed to proliferate its proliferation capacity A1 (exposed to F</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is able to significantly proliferate its proliferation capacity</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>Treatment of intra-splintly transplanted fetal shapes of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-thre-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-thre-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl has the ability to proliferate its proliferation capacity A</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>Treatment of intrasplens transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>Treatment of intrasplensally transplanted fetal cells of different origin with gasin-spared inhibitors fumonisin B1, D-treo-1-phenyl-2-decanoyl-3-morpholyl-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoyl-3-pyrrolidine-1-propanol-HCl has significantly impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>Treatment of intrasplensally transplanted liver cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may impair its A1 proliferation capacity (when proliferate to F</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with inhibitors of gangium synthesis fumonisine B1, D-threo-1-phenyl-2-decanoyl-1-propanol or D-1-phenyl-2-hexa-decanoylmine-3-pyrolidine-1-propanol-HCl, impairs its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl is proliferate to significantly compromise its proliferation capacity A1</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl may significantly proliferate its proliferation capacity A1 (when expos</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl will significantly proliferate its A1 proliferation capacity (when expos</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>Treatment of intrasplintly transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>Treatment of intraspontically transplanted fetal cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-traco-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl biosynthesis will significantly impair its ability to proliferate through pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, can significantly impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>Treatment of the human placenta of different origin with inhibitors of the gastrosine fumonisine B1, D-threo-1-phenyl-2-decanoyl-3-morpholino-1-propanol or D-1-treo-1-phenyl-2-hexa-decanoylamine-3-pyrolidino-1-propanol-HCl, may impair its ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>Treatment of transplant feet cells intrasplenomegaly of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholyl-1-propanol or D-1-phenyl-2-hexa-decanoylamino-3-pyrrolidine-1-propanol-HCl, impaired its ability to proliferate A1 (exposed to FGF</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>adult T cells will proliferate the undefined proliferation capability when transferred to lymphocytic hosts (image 6B).</text>
                    <arg n="0">adult T cells</arg>
                    <arg n="1">when transferred to lymphocytic hosts</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>androgen cancer cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>androgen cancer cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">androgen cancer cells</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>feet cells transplanted intrasplenically is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>feet cells transplanted intrasplentically is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">feet cells transplanted intrasplentically</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>fetal liver cells transplanted intrasplenically is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>fetal liver cells transplanted intrasplenically is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">fetal liver cells transplanted intrasplenically</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>human placenta can regain the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>human placenta is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>human placenta may have regained the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>human placenta may have regained the ability to proliferate indefinitely pregnancy (Figure 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>human placenta may proliferate recovered the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>human placenta, which are at rest under normal conditions, are able to proliferate strongly pregnancy.</text>
                    <arg n="0">human placenta</arg>
                    <arg n="1">pregnancy</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>ingenue T cells for adults has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">ingenue T cells for adults</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>ingenue T cells for adults, which are at rest under normal conditions, are able to proliferate strongly when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>ingenue T cells for adults, which are at rest under normal conditions, will proliferate when transferred to lymphonic hosts.</text>
                    <arg n="0">ingenue T cells for adults</arg>
                    <arg n="1">when transferred to lymphonic hosts</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>intra-splate transplant feet cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splate transplant feet cells</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>intra-splenic transplant fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>intra-splenic transplant fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>intra-splenic transplant fetal cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intra-splenic transplant fetal cells</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>intra-splintly transplanted fetal shapes is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intra-splintly transplanted fetal shapes</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>intrasplens transplanted liver cells has regained the ability to proliferate A1 indefinitely (after the introduction of the full-length wild type Stat5a) (Figure 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>intrasplens transplanted liver cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>intrasplens transplanted liver cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>intrasplens transplanted liver cells is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>intrasplens transplanted liver cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intrasplens transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>intrasplensally transplanted fetal cells is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>intrasplensally transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>intrasplensally transplanted fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>intrasplensally transplanted liver cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>intrasplensally transplanted liver cells is characterised by an proliferating proliferation capacity or a reduced programmed cell death capacity.</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>intrasplensally transplanted liver cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intrasplensally transplanted liver cells</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>intrasplintly transplanted fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasplintly transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>intrasponntically transplanted fetal cells is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intrasponntically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>intraspontically transplanted fetal cells may proliferate the A1 proliferation capacity (after the introduction of the full wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>intraspontically transplanted fetal cells proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>intraspontically transplanted fetal cells proliferate the A1 proliferation capacity indefinitely (after the introduction of the full wild-length Stat5a type) (picture 6B).</text>
                    <arg n="0">intraspontically transplanted fetal cells</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>the human placenta can regain the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>the human placenta can regain the ability to proliferate indefinitely through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>the human placenta can regain the ability to proliferate through pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">through pregnancy</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>the human placenta has regained the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>the human placenta is likely to proliferate the undefined proliferation capacity during pregnancy (picture 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>the human placenta will regain the ability to proliferate during pregnancy (Figure 6B).</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>the human placenta, which are at rest in normal conditions, have the ability to proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>the human placenta, which are at rest under normal conditions, are able to proliferate strongly during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>the human placenta, which are at rest under normal conditions, will proliferate during pregnancy.</text>
                    <arg n="0">the human placenta</arg>
                    <arg n="1">during pregnancy</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>transplant feet cells intrasplenomegaly is able to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>transplant feet cells intrasplenomegaly is likely to proliferate the A1 proliferation capability (after the introduction of the full wild-length state5a) (image 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>transplant feet cells intrasplenomegaly is observed to proliferate the A1 proliferation capacity (after introduction of complete wild-length Stat5a) (picture 6B).</text>
                    <arg n="0">transplant feet cells intrasplenomegaly</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
